The invention describes compositions that include a stevia sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and/or lingering of the stevia sweetener is decreased or eliminated.

The invention comprises radiolabeled MOEM type oligonucleotide of the formula (I), (I) wherein n, X.sup.1, X.sup.2, the linker (1), the linker (2), Q* and the receptor targeting moiety are as defined (I) the description. The radiolabeled oligonucleotides of the formula (I) can be used for the determination of the biodistribution and pharmacokinetics of the oligonucleotide in the tissue or body fluid.

##STR00001##

Disclosed herein is a substrate which includes a functional group protected with a photolabile group covalently attached to the substrate and a film of solvent thereof covering the substrate, where the thickness of the film is less than about 100 μm. Also disclosed herein are methods of preparing such substrates. Further disclosed are methods of synthesizing polymers, methods of synthesizing arrays of polymers and methods of removing photolabile protecting groups. These methods all employ covering the substrate with a thin film of solvent where the thickness of the film is less than 100 μm.

Disclosed herein is a substrate which includes a functional group protected with a photolabile group covalently attached to the substrate and a film of solvent thereof covering the substrate, where the thickness of the film is less than about 100 μm. Also disclosed herein are methods of preparing such substrates. Further disclosed are methods of synthesizing polymers, methods of synthesizing arrays of polymers and methods of removing photolabile protecting groups. These methods all employ covering the substrate with a thin film of solvent where the thickness of the film is less than 100 μm.

Disclosed are a furaneol glycoside compound, a pharmaceutical composition thereof, a preparation method therefor, and an application thereof. Specifically disclosed are a compound as represented by formula A-1, a pharmaceutically acceptable salt thereof or a crystal form thereof. Also disclosed is a pharmaceutical composition, which comprises the compound as represented by formula A-1, the pharmaceutically acceptable salt thereof, and a pharmaceutical adjuvant. Also disclosed is an application of the compound as represented by formula A-1, the pharmaceutically acceptable salt thereof, the crystal form thereof, or the pharmaceutical composition in the preparation of drugs. The drugs are drugs for treating inflammatory bowel diseases. The furaneol glycoside compound has a good effect of treating inflammatory bowel diseases, particularly ulcerative colitis.

##STR00001##

Disclosed are novel glycosylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a hydroxylated psilocybin derivative with a glycosyl compound.

The present invention refers to a method for the production of a catalytically active DNA molecule resulting in a significantly decreased amount of impurities in the catalytically active DNA molecule, to a catalytically active DNA molecule obtainable by such method and a pharmaceutical composition comprising such catalytically active DNA molecule as well as their use in a method for the prevention and/or treatment of a GATA-3-driven disease.

The present invention refers to a method for the production of a catalytically active DNA molecule resulting in a significantly decreased amount of impurities in the catalytically active DNA molecule, to a catalytically active DNA molecule obtainable by such method and a pharmaceutical composition comprising such catalytically active DNA molecule as well as their use in a method for the prevention and/or treatment of a GATA-3-driven disease.

A method of reversibly labeling a biomolecule including providing a linker molecule (11) having a first functional group (LG) with a reactive center, a second functional group (FG) with a reactive center, and a cleavable, e.g. hydrolyzable, moiety (A-B-C). The method further includes forming a covalent bond between the biomolecule (10) and the reactive center of the first functional group (LG), forming a covalent bond between a first label (L1) and the reactive center of the second functional group (FG), cleaving the cleavable moiety (A-B-C), e.g. hydrolyzing the hydrolyzable moiety, of the linker molecule (11) to remove the first label (L1) and to form a third functional group (W) with a reactive center, and forming a covalent bond between a further molecule and the reactive center of the third functional group (W) to reform the cleavable moiety, e.g. hydrolyzable moiety (A-B-C).

Provided are methods of synthesizing glycolipids. The methods combine chemical and enzymatic transformations to rapidly provide diverse natural and functionalized glycolipids in a high convergent matter. Stepwise enzymatic elongation of a carbohydrate chain of a common glycolipid precursor, compound (1), provides glycan intermediates of Formula (II), using sugar-nucleotides as glycosyl donors and glycosyltransferases as enzymes. Also provided are glycan intermediates of Formula (II) and alkene intermediates of Formula (IV) and methods of preparing same.